Stryker (SYK) Competitors

Stryker has lower revenue, but higher earnings than Cardinal Health. Cardinal Health is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

In the previous week, Stryker had 4 more articles in the media than Cardinal Health. MarketBeat recorded 53 mentions for Stryker and 49 mentions for Cardinal Health. Stryker's average media sentiment score of 1.42 beat Cardinal Health's score of 1.25 indicating that Stryker is being referred to more favorably in the news media.

Cardinal Health has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market. Comparatively, Stryker has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

Cardinal Health pays an annual dividend of $2.06 per share and has a dividend yield of 0.9%. Stryker pays an annual dividend of $3.52 per share and has a dividend yield of 1.0%. Cardinal Health pays out 28.5% of its earnings in the form of a dividend. Stryker pays out 36.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Cardinal Health has raised its dividend for 29 consecutive years and Stryker has raised its dividend for 32 consecutive years. Stryker is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Stryker has a net margin of 14.43% compared to Cardinal Health's net margin of 0.67%. Stryker's return on equity of 23.63% beat Cardinal Health's return on equity.

87.2% of Cardinal Health shares are held by institutional investors. Comparatively, 77.1% of Stryker shares are held by institutional investors. 0.1% of Cardinal Health shares are held by insiders. Comparatively, 4.6% of Stryker shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Cardinal Health currently has a consensus target price of $266.56, suggesting a potential upside of 15.35%. Stryker has a consensus target price of $386.28, suggesting a potential upside of 13.99%. Given Cardinal Health's stronger consensus rating and higher probable upside, research analysts clearly believe Cardinal Health is more favorable than Stryker.

Stryker has a net margin of 14.43% compared to Cencora's net margin of 0.79%. Cencora's return on equity of 125.45% beat Stryker's return on equity.

77.1% of Stryker shares are owned by institutional investors. Comparatively, 97.5% of Cencora shares are owned by institutional investors. 4.6% of Stryker shares are owned by company insiders. Comparatively, 0.4% of Cencora shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Stryker has higher earnings, but lower revenue than Cencora. Cencora is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

In the previous week, Stryker had 22 more articles in the media than Cencora. MarketBeat recorded 53 mentions for Stryker and 31 mentions for Cencora. Stryker's average media sentiment score of 1.42 beat Cencora's score of 1.35 indicating that Stryker is being referred to more favorably in the media.

Stryker currently has a consensus price target of $386.28, suggesting a potential upside of 13.99%. Cencora has a consensus price target of $370.85, suggesting a potential upside of 17.07%. Given Cencora's stronger consensus rating and higher probable upside, analysts plainly believe Cencora is more favorable than Stryker.

Stryker pays an annual dividend of $3.52 per share and has a dividend yield of 1.0%. Cencora pays an annual dividend of $2.40 per share and has a dividend yield of 0.8%. Stryker pays out 36.5% of its earnings in the form of a dividend. Cencora pays out 17.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has raised its dividend for 32 consecutive years and Cencora has raised its dividend for 15 consecutive years. Stryker is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Stryker has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, Cencora has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market.

DaVita currently has a consensus price target of $221.75, suggesting a potential upside of 26.07%. Stryker has a consensus price target of $386.28, suggesting a potential upside of 13.99%. Given DaVita's higher possible upside, research analysts clearly believe DaVita is more favorable than Stryker.

Stryker has higher revenue and earnings than DaVita. DaVita is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

In the previous week, Stryker had 52 more articles in the media than DaVita. MarketBeat recorded 53 mentions for Stryker and 1 mentions for DaVita. DaVita's average media sentiment score of 1.47 beat Stryker's score of 1.42 indicating that DaVita is being referred to more favorably in the media.

DaVita has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, Stryker has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

Stryker has a net margin of 14.43% compared to DaVita's net margin of 6.05%. Stryker's return on equity of 23.63% beat DaVita's return on equity.

90.1% of DaVita shares are held by institutional investors. Comparatively, 77.1% of Stryker shares are held by institutional investors. 1.9% of DaVita shares are held by insiders. Comparatively, 4.6% of Stryker shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Stryker has a net margin of 14.43% compared to Medtronic's net margin of 13.20%. Stryker's return on equity of 23.63% beat Medtronic's return on equity.

Medtronic currently has a consensus price target of $98.83, indicating a potential upside of 5.48%. Stryker has a consensus price target of $386.28, indicating a potential upside of 13.99%. Given Stryker's stronger consensus rating and higher possible upside, analysts plainly believe Stryker is more favorable than Medtronic.

Medtronic pays an annual dividend of $2.88 per share and has a dividend yield of 3.1%. Stryker pays an annual dividend of $3.52 per share and has a dividend yield of 1.0%. Medtronic pays out 77.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Stryker pays out 36.5% of its earnings in the form of a dividend. Medtronic has raised its dividend for 49 consecutive years and Stryker has raised its dividend for 32 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Medtronic has higher revenue and earnings than Stryker. Medtronic is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

In the previous week, Medtronic had 20 more articles in the media than Stryker. MarketBeat recorded 73 mentions for Medtronic and 53 mentions for Stryker. Stryker's average media sentiment score of 1.42 beat Medtronic's score of 1.40 indicating that Stryker is being referred to more favorably in the news media.

Medtronic has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market. Comparatively, Stryker has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market.

82.1% of Medtronic shares are held by institutional investors. Comparatively, 77.1% of Stryker shares are held by institutional investors. 0.3% of Medtronic shares are held by insiders. Comparatively, 4.6% of Stryker shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.